Pacer Advisors
SPRY icon

Pacer Advisors’s ARS Pharmaceuticals SPRY Stock Holding History

Pacer Advisors’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Buy
+1,062
New +$9.13K ﹤0.01% 2359
2024
Q3 		– Sell
-485
Closed -$4.13K – 2687
2024
Q2 		$4.13K Sell
485
-31
-6% -$275 ﹤0.01% 3651
2024
Q1 		$5.27K Buy
+516
New +$3.85K ﹤0.01% 3591

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Pacer Advisors's SPRY Position: Q2 2026 in Review

Pacer Advisors opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 1,062 shares worth $9K. The stake represents ﹤0.01% of the portfolio and ranks #2359 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in SPRY as recently as Q2 2024.

Pacer Advisors first reported a position in SPRY in Q1 2024 and has held it in 3 quarters since. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Pacer Advisors held 1,062 shares of ARS Pharmaceuticals worth $9K as of Q2 2026.
  • ARS Pharmaceuticals was a new Pacer Advisors position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2359 holding.
  • Pacer Advisors first reported a position in ARS Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.